

AMA の出現に何らかの関与を示唆しているが、PBC 特異性に関してはいまだ問題が残っているようである。

2. 胆汁中および胆管上皮に存在する菌体成分

Ide ら²⁵⁾ は、PBC 患者血清中に存在する IgM 型抗リピド A (LPS の活性部位) 抗体について検討しており、PBC では対照群に比し IgM 型抗リピド A 抗体の保有率が有意に高く、さらに UDCA 治療にてこの抗体価も減少すると報告している。また、PBC 肝組織内における LPS の組織内分布も検討し、肝細胞、クッパー細胞のみならず胆管にも LPS が存在していること、さらに UDCA 投与により胆管での LPS 発現が減弱することも報告している²⁶⁾。また、胆道感染症のみならず PBC や他の肝胆道系疾患でも、胆汁中にエンドトキシン (LPS) やグラム陽性菌の主要壁成分であるリポタイコ酸が存在しており²⁷⁻²⁹⁾、下記胆管自然免疫の PAMP (Pathogen-associated molecular pattern; 宿主免疫活性化作用をもつ微生物成分) として作用する。

3. 胆汁および肝組織中の細菌遺伝子

われわれは、胆汁から細菌 16S rRNA 遺伝子を PCR 法で増幅後、配列解読により菌種を同定した結果、PBC の胆汁中には対照疾患に比べグラム陽性球菌が優位に見られることを報告した²⁸⁾。また、Nilsson ら^{30,31)} は、PBC、PSC、非胆汁うっ滞性肝硬変、正常肝の肝組織を対象に、ヘリコバクター属および *H.pylori*、*H.bilis*、*H.pullorum*、*H.hepaticus* に特異的なプライマーを設定し PCR 法にて検出したところ、PBC や PSC などの慢性胆汁うっ滞性肝疾患の 80 ~ 90 % にヘリコバクター属が検出され、さらにそれらのほとんどが *H.pylori* も検出されたと報告している。ま

た、PBC 患者血清中の抗 PDC 抗体と抗 *H.pylori* 抗体とがよく相関することから、*H.pylori* が PBC の自己免疫現象に関わっていると考えられる³²⁾。しかし、Tanaka ら³³⁾ の報告では PBC 29 例中 1 例しか *H.pylori* が検出されず、またわれわれの検討でも *H.pylori* の関与は否定的な結果を得ている。

4. 類上皮肉芽腫と細菌

類上皮肉芽腫は PBC 症例の 80 % 前後に出現し³⁴⁾、特に障害胆管周囲にみられる場合、肉芽腫性胆管炎と呼称され診断価値の高い組織所見である (図 1)。一般病理学的に肉芽腫は感染や異物に対する生体反応として捉えられており、PBC の肉芽腫形成に何らかの感染症あるいは菌体成分 (特に結核菌などの抗酸菌) の関与が示唆される。近年、*Mycobacterium* の遺伝子がクローン病の病変部 (腸管壁や所属リンパ節) から分子生物学的に検出され、病態形成との関連性が示唆されている。Vilagut ら³⁵⁾ は肉芽腫形成を特徴とする *Mycobacteria* に注目し、PBC の肝組織中から非定型的抗酸菌である *Mycobacteria gordonae* の DNA が高率に検出されることを報告した。その後の追跡研究で、この菌種の 65 kDa Heat shock protein に対する抗体が PBC 全例で検出され、さらにヒト PDC-E2 や BCKD-E2 と交差反応を示すことも証明した³⁶⁻³⁸⁾。しかし、O'Donohue ら³⁹⁾ および Tanaka ら³³⁾ は否定的な成績を発表しており、PBC 肝組織内からの抗酸菌の検出に関して一定の結論は得られていない。

われわれは、PBC の肉芽腫形成と細菌との直接的な関連性を検討するため、マイクロダイセクション法と分子生物学的検討により肉芽腫部に存在する菌種を同定した。その結果、種々の腸内細菌由来の遺伝子が検出されたが、*Propionibacterium acnes* (*P.acnes*) が主




図1 PBCの肉芽腫性胆管炎

慢性非化膿性破壊性胆管炎に隣接して肉芽腫形成 (Gra) を認める。

たるクローンとして存在していることを報告し⁴⁰⁾、*P.acnes* 菌に対する抗体を用いた免疫染色でも肉芽腫部に陽性所見が見られた (図2)。*P.acnes* は全身性肉芽腫性疾患であるサルコイドーシスの病原菌としても注目されている菌種である⁴¹⁾。*P.acnes* の異常な集積と同菌体に対する免疫反応がPBCの肉芽腫形成の主たる要因であると示唆されるが、胆管炎などその他の病態形成における*P.acnes* の関与については不明である。

5. クラミジア感染症

2002年、Abdulkarimら^{42,43)}による米国消化器病学会およびEASLでの発表を機に、PBCとクラミジアとの関連性が注目されている。彼らは、クラミジア肺炎抗原に対する抗体を用いて免疫組織化学的検討を行ったところ、PBC肝の全例(25例)およびPSCの39例中6例で肝細胞内に陽性所見を認めたが、アルコール性肝疾患(40例)やC型慢性肝炎(22例)では陰性であったと報告した。しかし、Leungら⁴⁴⁾は、ヒトに対して病原性を示す*C.pneumoniae*、*C.trachomatis*を抗原としてPBC患者血清と反応させた結果、AMA陽性のPBC血清のうち91%が陽性で、AMA陰性のPBC血清では21%、対照群で




図2 *P.acnes* 菌体の免疫組織化学的検出

抗*P.acnes* モノクローナル抗体 (PAB抗体、東京医科歯科大学江石先生より分与) を用いた免疫組織化学的染色で、PBCの肉芽腫 (Gra) に陽性所見を認める。矢印は障害を伴った小葉間胆管。

は5%以下であったが、PCRや免疫組織化学的手法を用いて肝組織中からはクラミジアを検出することはできなかつたと報告しており、クラミジアとPBCとの関連性について疑問を投げかけた。クラミジアは性病性リンパ肉芽腫 (LGV) の原因菌でもあり、肉芽腫形成を起こし得る点でPBCと類似性がある。今後、追跡データの報告が待たれる領域である。

6. *Novosphingobium aromaticivorans* (*N.aromaticivorans*)

Selmiら⁴⁵⁾は、蛋白データベースよりヒトPDC-E2の抗原決定基領域に高いホモロジーを示すペプチドを検索し、ヒトPDC-E2に類似する2種の蛋白(47kDaと50kDa)を有する*N.aromaticivorans*に注目した。*N.aromaticivorans*は、土壌など自然界に存在するグラム陰性好気性菌で、xenobioticな有機化合物やエストロゲンを代謝する環境菌である。PDC-E2抗体陽性のPBC血清すべてが*N.aromaticivorans*の47kDa、50kD蛋白共に交差反応性を示し、さらに大腸菌に比し100~1,000倍の反応性を示した。また、糞便中

からも *N.aromaticivorans* 由来の遺伝子が検出され、PBC 原因菌の候補として報告している。

3. PBC の病因とウイルス感染症

PBC 患者に出現する AMA のイムノグロブリン型は IgG3 型と IgM 型が主であり⁴⁶⁾、末梢血リンパ球からの IgG3 分泌⁴⁷⁾、さらに PBC 患者では血中 IgG3 濃度が健常人に比べ高いこと⁴⁸⁾が報告されている。IgG3 は自己免疫疾患の誘因となり得るある種のウイルス感染症の際に認められることより、PBC とウイルス感染症との関連性が示唆される。また、非 PBC 症例の培養胆管細胞に PBC 患者由来のリンパ節抽出液を添加すると、胆管細胞から PDC-E2, E3-binding protein (Protein X) が表出されることが報告されており、ウイルスや細菌を含め何らかの感染性因子の関与が示唆されている⁴⁹⁾。

1. β レトロウイルス

近年、PBC とレトロウイルスとの関連性が注目されている。1988 年、Munoz ら⁵⁰⁾が、human immunodeficiency virus-1 (HIV-1) に対する抗体が PBC 患者血清中に存在していることを報告した。当初、擬陽性と考えられていたが、シェーグレン症候群や SLE などの自己免疫性疾患でも同様な血清学的データが報告され^{51,52)}、自己免疫現象における HIV-1 の関与が想定された。その後、1998 年に Mason ら⁵³⁾は、HIV-1 の p24 gag 蛋白および Human intracisternal A-type particle (HIAP) に対する抗体を調べた結果、p24 gag 蛋白に対する抗体が PBC の 35%、SLE の 29%、健常者の 4% で検出され、HIAP に対する抗体が PBC の 51%、SLE の 58%、健常者の 4% で検出され、これらレトロウイルス蛋白をトリガーとした分子相同性による自己免疫

反応が PBC を含めた自己免疫性疾患の病態に關与していることを示唆した。その後、Xu ら^{54,55)}は PBC 患者から得られたヒト胆管細胞の cDNA ライブラリーより、mouse mammary tumor virus (MMTV) およびヒト乳癌組織よりクローニングされた β レトロウイルスと類似した塩基配列を有する cDNA 断片を検出し、PBC のリンパ節におけるウイルス粒子の存在、さらに MMTV が正常胆管細胞からの自己抗原 (PDC-E2) を表出させ得ることも証明している。現在のところ、PBC の原因としてのウイルス感染を示唆する最も有力な報告である。

2. その他のウイルス

Minuk ら⁵⁶⁾は、レオウイルス (Reovirus type 3) に対する血中抗体を検討し、PBC や PSC ではその他の慢性肝疾患や健常人に比し抗体の陽性率が有意に高く、抗体価も高いが、肝生検材料を使った免疫組織化学的検討ではレオウイルスを証明できなかったと報告している。また、Morshed ら⁵⁷⁾は、PBC 患者の末梢単核球、肝組織、唾液から Epstein-Barr virus (EBV) を PCR 法にて検出し、他の肝疾患群に比し PBC で有意に高率であることから、PBC 患者では EBV 感染に対する免疫反応が低下しており、PBC の病態形成に關与している可能性を述べている。

4. 胆管周囲の微小環境と胆管系自然免疫

肝内胆管は detergents や菌体成分および産生物質などの PAMP に対する固有の防御機構を有しており、生理学的および病的状態で胆管細胞はあらゆる免疫応答を示す。例えば、PBC の胆管上皮には MHC class II が異常発現しており、胆管細胞自身が何らかの抗原を提示していると考えられる⁵⁸⁾。また、




図3 CD1dの免疫組織化学的検出
PBCの肉芽腫 (Gra) にCD1dの発現を認める。

PBCの胆管上皮には *in vivo*, *in vitro* に関わらず PDC-E2 の異常発現がみられ^{59, 60)}, PDC-E2 と交差反応する外来性抗原(細菌由来など)の異常集簇であると考えられている^{61, 62)}. PBCの門脈域にはこのような菌体成分に対する免疫応答を示唆する病理学的所見がみられ, 胆管細胞と菌体成分との直接的な相互作用も PBCの病態解明に重要な課題である。

1. CD1d と Natural killer-T (NKT) 細胞

CD1d は MHC class I 様の抗原提示分子で, 糖脂質成分(主に細菌に由来する)を T 細胞に提示する分子群である. PBCの胆管上皮および肉芽腫に CD1d の発現が見られ, 何らかの菌体成分が抗原提示されている可能性が示唆される(図3)⁶³⁾. PBCの障害胆管周囲には, 燐脂質成分(胆汁に由来)を含む泡沫細胞が多数出現しており, これらの細胞が細菌壁成分である LPS(グラム陰性菌)やリポタイコ酸(グラム陽性菌)などの脂質成分や胆汁中の脂質成分の抗原提示に関与している可能性がある。

NKT 細胞は NK 細胞マーカーと T 細胞受容体を共有するユニークな細胞集団であり, 上記 CD1d 分子と結合した糖脂質を認識する細胞である⁶⁴⁾. また, NKT 細胞は IFN- γ や



図4 TLR4の免疫染色

PBCの小葉間胆管(矢印)および細胆管(矢頭)にTLR4の発現を認め, 小葉間胆管は膜状の発現を示す。

IL-4 などのサイトカインの産生により Th1 や Th2 型 T 細胞への誘導を促し, また Fas-Fas リガンドを介したアポトーシスを誘導する細胞障害性エフェクター細胞としても作用する. この NKT 細胞が PBCの肝組織内, 特に障害胆管周囲で増加しており, 胆管から CD1d と共に表出されている菌体由来の糖脂質成分を認識し, PBC 特異的な胆管周囲の Th1 型サイトカインネットワークの形成や胆管細胞のアポトーシス誘導に加担している可能性がある⁶⁵⁻⁶⁸⁾.

2. スカベンジャー受容体

マクロファージ・スカベンジャー受容体(MSR)は酸化 LDL と結合する受容体であり, 脂質代謝産物など生体内の変性産物の処理や, LPS, リポタイコ酸などの糖脂質成分に対する生体防御などさまざまな機能を有する. 特にクラス B-1 型の MSR (SRB1) は肝臓で発現しており, 血中から胆汁中へのリポ蛋白やコレステロール輸送に重要な役割を果たす. Tsuneyama ら^{27, 69)} は SRB1 抗体を用いた免疫組織化学的検討にて, SRB1 は疾患に関わりなく類洞内皮細胞や Kupffer 細胞, および門脈域に浸潤する単球細胞の一部に発

現が認められ、また PBC の肉芽腫を構成する類上皮細胞にも発現があることを示している。これらの SRB1 陽性単核細胞は、肝類洞内や門脈域内に流入したさまざまな生体内変性物質や外来抗原の貪食・処理に重要な役割を果たしていると考えられ、さらに PBC では肉芽腫形成にも関与していることを示唆する所見である。

3. Monocyte chemotactic protein (MCP)

MCP ファミリーは、主にモノサイトから産生される強力な C-C 型 chemoattractant cytokine (ケモカイン) である。このうち MCP-1 は小葉間胆管や増生細胆管に恒常的に発現しており^{69,70)}、また、胆管細胞は IL-1 や TNF- α などの proinflammatory cytokine の存在下で MCP-1 産生亢進を示す⁷⁰⁾。また、MCP-2, MCP-3 陽性の分化したマクロファージが PBC の障害胆管周囲や肉芽腫周囲に浸潤している⁶⁹⁾。これらの所見より、PBC の胆管や門脈域に存在する菌体成分に対する反応として MCP, TNF- α , IL-1 などのケモカインやサイトカインが胆管周囲で誘導され、単核球の動員による PBC 特異的な胆管病変形成や肉芽腫形成に加担していると推測される⁶⁹⁾。

4. 胆管細胞の自然免疫機構

細菌などの微生物に対する免疫応答である自然免疫機構は、マクロファージなどの免疫担当細胞のみならず腸管上皮などの上皮細胞も有しており、特にクローン病や潰瘍性大腸炎などの慢性炎症性腸疾患では自然免疫の破綻または異常が病態形成に関与している。われわれは細菌と胆管病変との直接的な関連性を検討するため、細胞膜結合型菌体認識受容体である Toll-like receptor (TLR) の発現について検討した。その結果、胆管細胞は TLR4 (LPS の受容体) および関連因子 (MD-2)

の発現があり、LPS 刺激に対して細胞内シグナル伝達分子である NF- κ B が活性化され、TNF- α の産生が誘導されることを報告した²⁹⁾。また、免疫組織化学的検討により肝内胆管は TLR4 を発現していることを確認しており (図 4)、生体内でも胆管細胞は LPS などの PAMP を認識し、胆管固有の自然免疫機構を形成していると考えられる。その他、胆管細胞は 2 本鎖 RNA の受容体である TLR3 も発現しており、ウイルスを直接認識し得る可能性がある。なお、マウスを用いた検討では、上記レトロウイルスの項で記載した mouse mammary tumor virus (MMTV) の認識には TLR4 を使うとの報告もある⁷¹⁾。PBC の病態形成に胆管系自然免疫機構がどのように関与しているかは現在のところ不明であるが、われわれは微生物に対する過剰な生体反応またはトレランスの破綻が PBC の胆管炎の発生に加担していると想定している。

4 まとめ

PBC の病態発生機序として、ヒト PDC-E2 と類似した外来性抗原、特に微生物由来ペプチドとの分子相同性による自己免疫機序が、現在のところ最も有力な仮説であろう。分子生物学的または血清学的検討にていくつかの菌種、ウイルスが候補として報告されているが、特に微生物自体の検出に関しては賛否両論である。考えられる理由として、対象とした PBC 患者の病期や肝組織検体の違い (病初期 vs 肝硬変期、針生検 vs 移植肝)、さらに分子生物学的検出ではプライマー配列の特異性とデザインによる PCR 感度の相違に起因するところが多いようである。また、PBC の病態発生を自然免疫と獲得免疫の 2 段階の免疫応答の異常 (または破綻) で想定

した場合、微生物は初段階時の自然免疫における initiation として関与するだけで、AMA の出現や胆管破壊などの獲得免疫による病態発生時には微生物の存在を必要としないのかもしれない。PBC のみならず PSC などの肝胆道系疾患でも病態形成に微生物の関与が十分に考えられ、今後の更なる報告が待たれる。

文 献

- 1) Nakanuma Y, Ohta G : Histometric and serial section observations of the intrahepatic bile ducts in primary biliary cirrhosis. *Gastroenterology* 76 : 1326-1332, 1979
- 2) Kaplan MM : Primary biliary cirrhosis. *N Engl J Med* 335 : 1570-1580, 1996
- 3) Gershwin ME, Mackay IR, Sturgess A et al : Identification and specificity of a cDNA encoding the 70 kd mitochondrial antigen recognized in primary biliary cirrhosis. *J Immunol* 138 : 3525-3531, 1987
- 4) Surh CD, Ahmed-Ansari A, Gershwin ME : Comparative epitope mapping of murine monoclonal and human autoantibodies to human PDH-E2, the major mitochondrial autoantigen of primary biliary cirrhosis. *J Immunol* 144 : 2647-2652, 1990
- 5) Fussey SP, Ali ST, Guest JR et al : Reactivity of primary biliary cirrhosis sera with *Escherichia coli* dihydrolipoamide acetyltransferase (E2p) : characterization of the main immunogenic region. *Proc Natl Acad Sci U S A* 87 : 3987-3991, 1990
- 6) Shimoda S, Nakamura M, Ishibashi H et al : Molecular mimicry of mitochondrial and nuclear autoantigens in primary biliary cirrhosis. *Gastroenterology* 124 : 1915-1925, 2003
- 7) Kita H, Lian ZX, Van de Water J et al : Identification of HLA-A2-restricted CD8 (+) cytotoxic T cell responses in primary biliary cirrhosis: T cell activation is augmented by immune complexes cross-presented by dendritic cells. *J Exp Med* 195 : 113-123, 2002
- 8) Shimoda S, Nakamura M, Ishibashi H et al : HLA DRB4 0101-restricted immunodominant T cell autoepitope of pyruvate dehydrogenase complex in primary biliary cirrhosis: evidence of molecular mimicry in human autoimmune diseases. *J Exp Med* 181 : 1835-1845, 1995
- 9) Van de Water J, Ishibashi H, Coppel RL et al : Molecular mimicry and primary biliary cirrhosis: premises not promises. *Hepatology* 33 : 771-775, 2001
- 10) Burroughs AK, Rosenstein IJ, Epstein O et al : Bacteriuria and primary biliary cirrhosis. *Gut* 25 : 133-137, 1984
- 11) Morreale M, Tsirigotis M, Hughes MD et al : Significant bacteriuria has prognostic significance in primary biliary cirrhosis. *J Hepatol* 9 : 149-158, 1989
- 12) Ohno N, Ota Y, Hatakeyama S et al : A patient with *E.coli*-induced pyelonephritis and sepsis who transiently exhibited symptoms associated with primary biliary cirrhosis. *Intern Med* 42 : 1144-1148, 2003
- 13) Bogdanos DP, Baum H, Butler P et al : Association between the primary biliary cirrhosis specific anti-sp100 antibodies and recurrent urinary tract infection. *Dig Liver Dis* 35 : 801-805, 2003
- 14) Parikh-Patel A, Gold EB, Worman H et al : Risk factors for primary biliary cirrhosis in a cohort of patients from the united states. *Hepatology* 33 : 16-21, 2001
- 15) O'Donohue J, Workman MR, Rolando N et al : Urinary tract infections in primary biliary cirrhosis and other chronic liver diseases. *Eur J Clin Microbiol Infect Dis* 16 : 743-746, 1997
- 16) Floreani A, Bassendine MF, Mitchison H et al : No specific association between primary biliary cirrhosis and bacteriuria? *J Hepatol* 8 : 201-207, 1989
- 17) Sayers TJ, Baum H : Possible cross-reactivity of human anti-mitochondrial antibodies with membrane vesicles of *Paracoccus denitrificans*. *Biochem Soc Trans* 4 : 138-139, 1976
- 18) Flannery GR, Burroughs AK, Butler P et al : Antimitochondrial antibodies in primary biliary cirrhosis recognize both specific peptides and shared epitopes of the M2 family of antigens. *Hepatology* 10 : 370-374, 1989
- 19) Bogdanos DP, Baum H, Grasso A et al : Microbial mimics are major targets of crossreactivity with human pyruvate dehydrogenase in primary biliary cirrhosis. *J Hepatol* 40 : 31-39, 2004
- 20) Stemerowicz R, Hopf U, Moller B et al : Are antimitochondrial antibodies in primary biliary cirrhosis induced by R (rough) -mutants of enterobacteriaceae? *Lancet* 2: 1166-1170, 1988

- 21) Yeaman SJ, Fussey SP, Mutimer DJ et al : M2 autoantigens in primary biliary cirrhosis. *Lancet* 1 : 103, 1989
- 22) Hopf U, Moller B, Stemerowicz R et al : Relation between *Escherichia coli* R (rough) -forms in gut, lipid A in liver, and primary biliary cirrhosis. *Lancet* 2 : 1419-1422, 1989
- 23.) Butler P, Valle F, Hamilton-Miller JM et al : M2 mitochondrial antibodies and urinary rough mutant bacteria in patients with primary biliary cirrhosis and in patients with recurrent bacteriuria. *J Hepatol* 17 : 408-414, 1993
- 24) 川口直美, 田中 篤, 小野塚靖, 他 : PBC および非 PBC 血清と *E.coli* 由来 PDC-E2 との交差反応性 (抄録). *肝臓* 43 (suppl) : A186, 2002
- 25) Ide T, Sata M, Nakano H et al : Increased serum IgM class anti-lipid A antibody and therapeutic effect of ursodeoxycholic acid in primary biliary cirrhosis. *Hepatogastroenterology* 44 : 1569-1573, 1997
- 26) Sasatomi K, Noguchi K, Sakisaka S et al : Abnormal accumulation of endotoxin in biliary epithelial cells in primary biliary cirrhosis and primary sclerosing cholangitis. *J Hepatol* 29 : 409-416, 1998
- 27) Tsuneyama K, Harada K, Kono N et al : Scavenger cells with gram-positive bacterial lipoteichoic acid infiltrate around the damaged interlobular bile ducts of primary biliary cirrhosis. *J Hepatol* 35 : 156-163, 2001
- 28) Hiramatsu K, Harada K, Tsuneyama K et al : Amplification and sequence analysis of partial bacterial 16S ribosomal RNA gene in gallbladder bile from patients with primary biliary cirrhosis. *J Hepatol* 33 : 9-18, 2000
- 29) Harada K, Ohira S, Isse K et al : Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. *Lab Invest* 83 : 1657-1667, 2003
- 30) Nilsson HO, Castedal M, Olsson R et al : Detection of *Helicobacter* in the liver of patients with chronic cholestatic liver diseases. *J Physiol Pharmacol* 50 : 875-882, 1999
- 31) Nilsson HO, Taneera J, Castedal M et al : Identification of *Helicobacter pylori* and other *Helicobacter* species by PCR, hybridization, and partial DNA sequencing in human liver samples from patients with primary sclerosing cholangitis or primary biliary cirrhosis. *J Clin Microbiol* 38 : 1072-1076, 2000
- 32) Dohmen K, Shigematsu H, Miyamoto Y et al : Atrophic corpus gastritis and *Helicobacter pylori* infection in primary biliary cirrhosis. *Dig Dis Sci* 47 : 162-169, 2002
- 33) Tanaka A, Prindiville TP, Gish R et al : Are infectious agents involved in primary biliary cirrhosis? A PCR approach. *J Hepatol* 31 : 664-671, 1999
- 34) Nakanuma Y, Ohta G : Quantitation of hepatic granulomas and epithelioid cells in primary biliary cirrhosis. *Hepatology* 3 : 423-427, 1983
- 35) Vilagut L, Vila L, Pares A et al : *Mycobacterium gordonae* DNA in liver tissue of patients with primary biliary cirrhosis (abstract). *J Hepatol* 21 : 87, 1994
- 36) Vilagut L, Vila J, Vinas O et al : Cross-reactivity of anti-*Mycobacterium gordonae* antibodies with the major mitochondrial autoantigens in primary biliary cirrhosis. *J Hepatol* 21 : 673-677, 1994
- 37) Vilagut L, Pares A, Vinas O et al : Antibodies to mycobacterial 65-kD heat shock protein cross-react with the main mitochondrial antigens in patients with primary biliary cirrhosis. *Eur J Clin Invest* 27 : 667-672, 1997
- 38) Vilagut L, Pares A, Rodes J et al : Mycobacteria-related to the aetiopathogenesis of primary biliary cirrhosis? *J Hepatol* 24 : 125, 1996
- 39) O'Donohue J, Fidler H, Garcia-Barcelo M et al : Mycobacterial DNA not detected in liver sections from patients with primary biliary cirrhosis. *J Hepatol* 28 : 433-438, 1998
- 40) Harada K, Tsuneyama K, Sudo Y et al : Molecular identification of bacterial 16S ribosomal RNA gene in liver tissue of primary biliary cirrhosis: is *Propionibacterium acnes* involved in granuloma formation? *Hepatology* 33 : 530-536, 2001
41. Ishige I, Usui Y, Takemura T et al : Quantitative PCR of mycobacterial and propionibacterial DNA in lymph nodes of Japanese patients with sarcoidosis. *Lancet* 354 : 120-123, 1999
- 42) Abdulkarim A, Petrovic L, Kim R et al : Primary biliary cirrhosis: an infectious disease caused by *chlamydia pneumoniae* (abstract). *Gastroenterology* 122 : A641, 2002
- 43) Abdulkarim A, Petrovic L, Kim R et al : Primary biliary cirrhosis: an infectious disease caused by *chlamydia pneumoniae*? (abstract). *J Hepatol* 36 (suppl 1) : 152, 2002
- 44) Leung PS, Park O, Matsumura S et al : Is there a relation between *Chlamydia* infection and primary

- biliary cirrhosis? *Clin Dev Immunol* 10 : 227-233, 2003
- 45) Selmi C, Balkwill DL, Invernizzi P et al : Patients with primary biliary cirrhosis react against a ubiquitous xenobiotic-metabolizing bacterium. *Hepatology* 38 : 1250-1257, 2003
 - 46) Riggione O, Stokes RP, Thompson RA : Predominance of IgG3 subclass in primary cirrhosis. *Br Med J (Clin Res Ed)* 286 : 1015-1016, 1983
 - 47) Bird P, Calvert JE, Mitchison H et al : Lymphocytes from patients with primary biliary cirrhosis spontaneously secrete high levels of IgG3 in culture. *Clin Exp Immunol* 71 : 475-480, 1988
 - 48) Surh CD, Cooper AE, Coppel RL et al : The predominance of IgG3 and IgM isotype antimitochondrial autoantibodies against recombinant fused mitochondrial polypeptide in patients with primary biliary cirrhosis. *Hepatology* 8 : 290-295, 1988
 - 49) Sadamoto T, Joplin R, Keogh A et al : Expression of pyruvate-dehydrogenase complex PDC-E2 on biliary epithelial cells induced by lymph nodes from primary biliary cirrhosis. *Lancet* 352 : 1595-1596, 1998
 - 50) Munoz S, Ballas S, Norberg R et al : Antibodies to human immunodeficiency virus (HIV) in primary biliary cirrhosis (abstract). *Gastroenterology* 94 : A574, 1988
 - 51) Talal N, Dauphinee MJ, Dang H et al : Detection of serum antibodies to retroviral proteins in patients with primary Sjogren's syndrome (autoimmune exocrinopathy). *Arthritis Rheum* 33 : 774-781, 1990
 - 52) Talal N, Garry RF, Schur PH et al : A conserved idio type and antibodies to retroviral proteins in systemic lupus erythematosus. *J Clin Invest* 85 : 1866-1871, 1990
 - 53) Mason AL, Xu L, Guo L et al : Detection of retroviral antibodies in primary biliary cirrhosis and other idiopathic biliary disorders. *Lancet* 351 : 1620-1624, 1998
 - 54) Xu L, Sakalian M, Shen Z et al : Cloning the human betaretrovirus proviral genome from patients with primary biliary cirrhosis. *Hepatology* 39 : 151-156, 2004
 - 55) Xu L, Shen Z, Guo L et al : Does a betaretrovirus infection trigger primary biliary cirrhosis? *Proc Natl Acad Sci U S A* 100 : 8454-8459, 2003
 - 56) Minuk GY, Rascenin N, Paul RW et al : Reovirus type 3 infection in patients with primary biliary cirrhosis and primary sclerosing cholangitis. *J Hepatol* 5 : 8-13, 1987
 - 57) Morshed SA, Nishioka M, Saito I et al : Increased expression of Epstein-Barr virus in primary biliary cirrhosis patients. *Gastroenterol Jpn* 27 : 751-758, 1992
 - 58) Nakanuma Y, Kono N : Expression of HLA-DR antigens on interlobular bile ducts in primary biliary cirrhosis and other hepatobiliary diseases: an immunohistochemical study. *Hum Pathol* 22 : 431-436, 1991
 - 59) Tsuneyama K, Van De Water J, Van Thiel D et al : Abnormal expression of PDC-E2 on the apical surface of biliary epithelial cells in patients with antimitochondrial antibody-negative primary biliary cirrhosis. *Hepatology* 22 : 1440-1446, 1995
 - 60) Joplin R, Lindsay JG, Johnson GD et al : Membrane dihydrolipoamide acetyltransferase (E2) on human biliary epithelial cells in primary biliary cirrhosis. *Lancet* 339 : 93-94, 1992
 - 61) Harada K, Van de Water J, Leung PS et al : *In situ* nucleic acid hybridization of pyruvate dehydrogenase complex-E2 in primary biliary cirrhosis: pyruvate dehydrogenase complex-E2 messenger RNA is expressed in hepatocytes but not in biliary epithelium. *Hepatology* 25 : 27-32, 1997
 - 62) Harada K, Sudo Y, Kono N et al : *In situ* nucleic acid detection of PDC-E2, BCOADC-E2, OGDC-E2, PDC-E1alpha, BCOADC-E1alpha, OGDC-E1, and the E3 binding protein (protein X) in primary biliary cirrhosis. *Hepatology* 30 : 36-45, 1999
 - 63) Tsuneyama K, Yasoshima M, Harada K et al : Increased CD1d expression on small bile duct epithelium and epithelioid granuloma in livers in primary biliary cirrhosis. *Hepatology* 28 : 620-623, 1998
 - 64) Spada FM, Koezuka Y, Porcelli SA : CD1d-restricted recognition of synthetic glycolipid antigens by human natural killer T cells. *J Exp Med* 188 : 1529-1534, 1998
 - 65) Kita H, Naidenko OV, Kronenberg M et al : Quantitation and phenotypic analysis of natural killer T cells in primary biliary cirrhosis using a human CD1d tetramer. *Gastroenterology* 123 : 1031-1043, 2002
 - 66) Harada K, Isse K, Tsuneyama K et al : Accumulating CD57+ CD3+ natural killer T cells are related to intrahepatic bile duct lesions in primary biliary cirrhosis. *Liver Int* 23 : 94-100, 2003
 - 67) Harada K, Ozaki S, Gershwin ME et al : Enhanced

- apoptosis relates to bile duct loss in primary biliary cirrhosis. *Hepatology* 26 : 1399–1405, 1997
- 68) Harada K, Van de Water J, Leung PS et al : *In situ* nucleic acid hybridization of cytokines in primary biliary cirrhosis: predominance of the Th1 subset. *Hepatology* 25 : 791–796, 1997
- 69) Tsuneyama K, Harada K, Yasoshima M et al : Monocyte chemotactic protein-1, -2, and -3 are distinctively expressed in portal tracts and granulomata in primary biliary cirrhosis: implications for pathogenesis. *J Pathol* 193 : 102–109, 2001
- 70) Morland CM, Fear J, McNab G et al : Promotion of leukocyte transendothelial cell migration by chemokines derived from human biliary epithelial cells *in vitro*. *Proc Assoc Am Physicians* 109 : 372–382, 1997
- 71) Rassa JC, Meyers JL, Zhang Y et al : Murine retroviruses activate B cells via interaction with toll-like receptor 4. *Proc Natl Acad Sci USA* 99 : 2281–2286, 2002

* * *

Human cord blood- and bone marrow-derived CD34⁺ cells regenerate gastrointestinal epithelial cells

FUMIHIKO ISHIKAWA,¹ MASAKI YASUKAWA,* SHURO YOSHIDA,
KEI-ICHIRO NAKAMURA,[†] YOSHIHISA NAGATOSHI,[‡] TAKAAKI KANEMARU,¹
KAZUYA SHIMODA, SHINJI SHIMODA, TOSHIHIRO MIYAMOTO, JUN OKAMURA,
LEONARD D. SHULTZ,[§] AND MINE HARADA

Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan; *First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Japan; [†]Second Department of Anatomy, Kurume University, Kurume, Japan; [‡]Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan; ¹Morphology Core, Kyushu University, Fukuoka, Japan; and [§]The Jackson Laboratory, Bar Harbor, Maine, USA

© To read the full text of this article, go to <http://www.fasebj.org/cgi/doi/10.1096/fj.04-2396fje>; doi: 10.1096/fj.04-2396fje

SPECIFIC AIMS

In the present study, we aimed to clarify if human cord blood and bone marrow contained progenitor cells that would generate gastrointestinal epithelial cells in clinical and experimental transplantation settings.

PRINCIPAL FINDINGS

1. Three-dimensional analysis excludes the possibility of cell overlay

We analyzed gastrointestinal specimens derived from sex-mismatched female recipients of cord blood (CB), bone marrow (BM), and mobilized peripheral blood (MPB) transplantations to determine whether each hematopoietic cell source contained progenitor cells to generate gastrointestinal epithelial cells. To rule out the possibility of cell overlay using FISH analysis, we performed detailed analysis on signals for a human Y chromosome probe using laser scanning confocal microscopy (Fig. 1). Fluorescent and Nomarsky images were obtained from intestinal specimens, which were subjected to FISH analysis using a Spectrum green-conjugated Y chromosome probe and nuclear staining with DAPI (Fig. 1A–E). To clarify the localization of signals for chromosomes inside or outside of nuclei, we obtained 12 serial images from different levels at 0.4 μ m intervals (Fig. 1F). X-Z imaging reconstructed from serial X-Y images demonstrated that the FITC-labeled signal for the human Y chromosome was localized inside the nucleus (Fig. 1G).

2. Generation of gastrointestinal epithelial cells in human allogeneic recipients

To further identify the types of donor-derived cells, we performed FISH analysis and immunostaining on the

same specimen, not using serial sections of the specimen. We obtained four types of information from each specimen; the nature of nuclei, contour of the cells, antigen expression, and origin of the cells. The FISH and immunofluorescence analyses for different portions of specimens demonstrated that the incidence of donor-derived epithelial cells was between 0.4% and 1.9%. In the present study using specimens derived from pediatric and juvenile recipients without experience of pregnancy, fetal-derived microchimerism can be excluded as a mechanism for the presence of Y chromosome⁺ cells. The three sources of stem cells, CB-, BM-, and MPB, contained stem/progenitor cells, which could give rise to epithelial cells in allogeneic recipients.

3. Human CB- and BM-derived CD34⁺ cells give rise to epithelial cells in NOD/SCID/ β 2M^{null} mice

Next, we examined the capacity of “purified” human progenitor cells in an experimental transplantation setting. We transplanted 1×10^5 human CB- or BM-derived CD34⁺ progenitor cells into newborn NOD/SCID/ β 2M^{null} mice, which exhibited extremely low activity of NK cells as well as complete lack of mature B cells and T cells. At 3 months post-transplantation, high levels of engraftment by human CD45⁺ cells and multilineage reconstitution of human progenitor cells (CD34⁺), myeloid lineage cells (CD33⁺), B-lineage cells (CD19⁺), and T-lineage cells (CD3⁺) were observed in the xenogeneic host BM. High levels of hematopoietic engraftment by human cells is considered essential to support a relatively low incidence of

¹ Correspondence: Kyushu University Graduate School of Medicine, Department of Medicine and Biosystemic Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: f_ishika@intmed1.med.kyushu-u.ac.jp




Figure 1. Localization of signal for Y chromosome in the nucleus. In sex-mismatched allogeneic transplantation, donor-derived intestinal epithelial cells were examined with FISH analyses. *A*) Low-magnified image showed that a coronal section of crypt contained a donor-derived cell (arrow) identified with the Spectrum green-conjugated Y chromosome probe. *B*) The existence of the male-derived cell was confirmed with Spectrum green-conjugated Y chromosome probe in a higher magnified view. *C*) Nomarsky imaging revealed the detailed morphology of the cells. *D*) Nuclei of the cells were stained with DAPI. *E*) Images of panels *B–D* merged. *F*) Signals for Y chromosome and nuclei staining are shown in twelve serial images obtained from different levels at 0.4 μm interval. *G*) The location of signal for human X chromosome was determined at the same level of nucleus by X-Z image.

generation of hematopoietic tissue-derived epithelial cells. Similar to the analysis of clinical specimens, the gastrointestinal tissues of recipient mice were analyzed for the presence of human cells by performing FISH analysis and immunofluorescent studies of the same specimens. The incidence of human CD34⁺ cell-derived epithelial cells in xenogeneic intestinal or gastric tissue was 0.23–0.58% in CB recipients and 0.15–0.30% in BM recipients.

4. The mechanism for the generation of human CB-derived intestinal epithelial cells

We examined the possibility of cell fusion as a mechanism for the generation of CB- or BM-derived epithelial cells. When we examined the presence of human cells in mesenteric lymphoid nodes, the vast majority of cells were dually positive for human X chromosome and human CD45 (Fig. 2A), showing that human CD34⁺ progenitor cells could effectively reconstitute lymphoid tissues of the recipient intestine. As no cytokeratin⁺ epithelial cells were stained with anti-human CD45 antibody, we performed double FISH analyses using human and murine chromosome probes and immunostaining for cytokeratin on the same specimen. Nomarsky imaging demonstrated that a human CB-derived

human X chromosome⁺ cell was identified in organized sequence of epithelial cells in villi (Fig. 2B). In Fig. 2C, a human X chromosome⁺ cell was positively stained with anti-cytokeratin antibody, suggesting that the human cell was an epithelial cell. We tested whether human X chromosome⁺ epithelial cells with




Figure 2. Human X chromosome-positive epithelial cell was not generated by the fusion between human cell and murine epithelial cell. Human CB-derived CD34⁺ cells were transplanted into newborn NOD/SCID/ $\beta 2\text{M}^{\text{null}}$ recipients. At 3 months post-transplantation, *in vivo* generation of human intestinal epithelial and lymphoid cells was examined by laser confocal microscopy. *A*) Lymphoid tissue derived from a recipient intestine was subjected to immunostaining with anti-human CD45 antibody (green) and FISH analysis with human X chromosome probe (red). The majority of the cells in lymphoid tissue of the recipient mice were human hematopoietic cells as judged by the positivity of human X chromosome and human CD45. *B–E*) After FISH analyses and immunofluorescent studies were performed on the same specimen derived from recipient intestine, four-color (FITC, Spectrum orange, Cy5, DAPI) analyses were executed with laser scanning confocal microscopy along with Nomarsky imaging. *B*) Nomarsky image showed that human cell identified with anti-human X chromosome probe (red) was identified in organized sequence of villi. *C*) The cell with human X chromosome was confirmed as an epithelial cell by positive staining with Cy5-conjugated anti-cytokeratin antibody. *D*) The majority of the cells in the same specimen were murine cells, which were identified with FITC-conjugated mouse pan-centromeric probe. The cell identified with human X chromosome probe did not possess any mouse centromeres in the nucleus. Bar represents 10 μm . *E*) The hybridization signal for human X chromosome was located inside nucleus as judged by X-Z image reconstructed from serial X-Y images. *F*) Such human cells were also identified at the bottom of crypt.




Figure 3. Schematic diagram.

donor chromosomes were generated due to the fusion of donor-derived progenitors and recipient-derived epithelial cells. Although the majority of epithelial cells had murine centromeres, simultaneous FISH analyses using species-specific probes demonstrated that the nucleus of the human X chromosome⁺ cell was not labeled with the mouse centromere probe (Fig. 2D), indicating that the human chromosome⁺ epithelial cell was not generated by fusion of human CD34⁺ cells and murine epithelial cells. X-Z imaging reconstructed from 10 slices of 0.3 μm serial X-Y images confirmed that the dot indicating the presence of human X chromosome was located inside the nucleus of the epithelial cell (Fig. 2E) and not was an artifact due to cell overlay. Such human X chromosome⁺ cells were identified both along villi and at the bottom of crypt (Fig. 2F), a candidate location of intestinal stem cells.

CONCLUSIONS AND SIGNIFICANCE

We have used clinical and experimental transplantation settings in order to examine the capacity of human hematopoietic progenitor cells to generate gastrointestinal epithelial cells in allogeneic and xenogeneic recipients.

In terms of technical issue, we successfully combined FISH analysis with immunofluorescent studies to identify donor chromosome⁺ cytokeratin⁺ cells. The simultaneous FISH and immunofluorescent studies of the same specimens, not using serial sections, enabled the

identification of donor-derived epithelial cells accurately. One of the criticisms against previous FISH studies was that a tiny dot indicating the presence of donor chromosome could be localized at a different level of the nucleus due to cell overlay. Both in allogeneic and xenogeneic transplantations, X-Z images, reconstructed from serial X-Y images captured by laser scanning confocal microscopy, clearly demonstrated that the hybridization signal for human chromosome existed inside the nucleus, which supported the specificity of FISH analyses in the present study. Our analyses of pediatric and juvenile recipients demonstrated that Y chromosome⁺ epithelial cells of gastrointestinal tract were derived from transplanted hematopoietic tissue-derived cells, not reminiscent of fetus-derived cells.

Considering the limited availability of clinical specimens and the controversy regarding the generation of BM-derived epithelial cells in clinical cases, we developed experimental xenotransplantation assays, in which purified human progenitor cells could be analyzed for their capacity. We here identified that human CB- and BM-derived CD34⁺ cells were capable of generating epithelial cells in vivo. Although the capacities of CB and BM did not differ significantly in the present study, CB could be used as precious source for allogeneic and autologous progenitor cells as well as BM in the future regenerative medicine.

Molecular mechanism underlying stem cell plasticity has yet to be understood. Cell fusion between donor-derived stem cells and mature cells of recipient origin may account for seemingly donor stem cell-derived progeny. As hepatocytes and myocytes are known to fuse in physiological condition, the mechanism for the generation of CB- and BM-derived gastrointestinal epithelial cells needs to be clarified. Sex chromosome painting in the FISH analysis of clinical specimens cannot determine the possibility of cell fusion as thin sections do not include the whole chromosomes. Xenogeneic assay enabled us to evaluate the possibility of cell fusion by using human chromosome probe and mouse centromere probe on the same specimens. Double FISH analyses demonstrated that the cells positive for human chromosome and cytokeratin were not labeled with anti-mouse centromere probe. Altogether, it is concluded that fusion between stem cells and epithelial cells is not the only mechanism at least in intestine and that human purified progenitor cells can regenerate intestinal epithelial cells across allogeneic and xenogeneic histocompatibility barrier. [E]

Tyrosine Kinase 2 Interacts with and Phosphorylates Receptor for Activated C Kinase-1, a WD Motif-Containing Protein¹

Takashi Haro,* Kazuya Shimoda,^{2*} Haruko Kakumitsu,* Kenjiro Kamezaki,* Akihiko Numata,* Fumihiko Ishikawa,* Yuichi Sekine,[†] Ryuta Muromoto,[†] Tadashi Matsuda,[†] and Mine Harada*

Receptor for activated C kinase (Rack)-1 is a protein kinase C-interacting protein, and contains a WD repeat but has no enzymatic activity. In addition to protein kinase C, Rack-1 also binds to Src, phospholipase C γ , and *ras*-GTPase-activating proteins. Thus, Rack-1 is thought to function as a scaffold protein that recruits specific signaling elements. In a cytokine signaling cascade, Rack-1 has been reported to interact with the IFN- $\alpha\beta$ receptor and Stat1. In addition, we show here that Rack-1 associates with a member of Jak, tyrosine kinase 2 (Tyk2). Rack-1 interacts weakly with the kinase domain and interacts strongly with the pseudokinase domain of Tyk2. Rack-1 associates with Tyk2 via two regions, one in the N terminus and one in the middle portion (aa 138–203) of Rack-1. Jak activation causes the phosphorylation of tyrosine 194 on Rack-1. After phosphorylation, Rack-1 is translocated toward the perinuclear region. In addition to functioning as a scaffolding protein, these results raise the possibility that Rack-1 functions as a signaling molecule in cytokine signaling cascades. *The Journal of Immunology*, 2004, 173: 1151–1157.

Many cytokines bind to specific cell surface receptors and activate members of the Janus family of protein tyrosine kinases (Jaks), which are associated with cytokine receptors (1). The activated Jaks phosphorylate the tyrosine residues of the receptors, thereby recruiting Stats and other signaling molecules into the activated receptor complex. Stats are then phosphorylated by Jaks, and are subsequently translocated to the nucleus, where they affect gene expression. This Jak-Stat signaling pathway is widely used by members of the cytokine receptor super family (2). There are four mammalian Jaks: Jak1, Jak2, Jak3, and tyrosine kinase 2 (Tyk2).³ Tyk2 has been identified as a novel protein kinase which can compensate for IFN- α nonresponsive mutated fibroblasts (3). IFN- α specifically activates Jak1 and Tyk2, which phosphorylate Stat 1 and 2. These activated Stats subsequently associate to form either Stat1 homodimers or the transcription factor ISGF-3, which then translocate to the nucleus to regulate gene expression (2, 4). Both Tyk2 and Jak1 were thought to be essential for signal transduction downstream of IFN- α in mutated fibroblasts, which are not responsive to IFN- α (4). However, using Tyk2-deficient mice, we and others have shown that Tyk2 has a restricted function and does not play a

major role in IFN- α signaling (5, 6). In contrast, Jak 1-null cells fail to respond to IFN- α (7). In addition, Stat1-null mice are defective in almost all IFN- α -induced responses (8, 9). Stat2-null mice also demonstrated an increased susceptibility to viral infection (10). Based on these data, the Jak1-Stat signaling pathway is thought to be essential for IFN- α signaling. Recently, we reported that Tyk2 was essential for IFN- α -induced B lymphocyte growth inhibition (11). Stat1 is not required for this IFN- α -mediated inhibition (12); therefore, other signaling molecules must exist downstream of activated Tyk2 to transduce the IFN- α signal inhibiting B lymphocyte growth. Thus, we performed a yeast two-hybrid screen for proteins that interact with Tyk2.

In this report, we identify receptor for activated C kinase (Rack)-1, originally described as a receptor for activated C kinase β , as a protein that interacts with Tyk2. Rack-1 has previously been reported to constitutively interact with the β long subunit of the type I IFNR (13), Jak1, Tyk2 (14), and Stat1 (15). We show here that Rack-1 associates with Jaks, and is phosphorylated on tyrosine residues by Jaks. This raises the possibility that Rack-1 functions as a signaling molecule in cytokine signaling cascades.

Materials and Methods

Abs and reagents

Anti-Rack-1, -Tyk2, -Jak1, -Jak2, and -Jak3 Abs were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). Anti-phosphotyrosine mAb (clone 4G10) was purchased from Upstate Biotechnology (Lake Placid, NY). Anti-c-Myc mAb was purchased from BD Clontech (Palo Alto, CA). Anti-Flag M2 mAb was purchased from Sigma-Aldrich (St. Louis, MO). Murine IFN- α was purchased from HyCult Biotechnology (Uden, The Netherlands).

Yeast two-hybrid screen

A cDNA encoding the kinase domain (aa 833–1187) of human Tyk2 was subcloned into the Gal DNA-binding domain plasmid pGBKT7 (BD Clontech), and was used as bait in a yeast two-hybrid screen of a human B lymphocyte cDNA library constructed in pACT (BD Clontech). Approximately 1.6×10^6 colonies were screened for activation of the ADE2, HIS3, and *lacZ* reporter genes using the host strain AH109. The inserts from positive library plasmids were then amplified by PCR and mapped by *Aba*I digestion. Plasmids were sequenced after isolation and bacterial transformation.

*First Department of Internal Medicine, Faculty of Medicine, and Medicine and Biosystemic Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan; and [†]Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University, Sapporo, Japan

Received for publication November 25, 2003. Accepted for publication May 5, 2004.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked *advertisement* in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

¹ This work was supported in part by a grant from the Japan Leukemia Foundation, a Grant for Clinical Research, and Grants-in-Aid for Scientific Research (Nos. 13218096, 15390302) from the Ministry of Education, Culture, Sports, Science and Technology in Japan.

² Address correspondence and reprint requests to Dr. Kazuya Shimoda, First Department of Internal Medicine, Faculty of Medicine, Kyushu University, 3-1-1 Maidashi, Higashi-ku, Fukuoka, Fukuoka 812-8582, Japan. E-mail address: kshimoda@inmed1.med.kyushu-u.ac.jp

³ Abbreviations used in this paper: Tyk2, tyrosine kinase 2; Rack, receptor for activated C kinase; PKC, protein kinase C.

Mammalian expression vector constructs

Murine Jak1, Jak2, Jak3, and human Tyk2 expression constructs were gifts from Dr. J. Ihle (St. Jude Children's Research Hospital, Memphis, TN). Kinase-negative versions of the Jak proteins were generated by mutating lysine (K833) to glutamine in murine Jak1 (Jak1 KE) and lysine (K882) to glutamine in murine Jak2 (Jak2 KE) (16).

The partial human Tyk2 cDNAs expressing the various domains (aa 1-450, 266-733, 600-1086, or 833-1187) indicated in Fig. 3A were generated by PCR, and were subcloned into pCMV-MyC (BD Clontech). The clone 4-86 cDNA (C-terminal region of Rack-1 encoding aa 137-317), whose gene product associated with Tyk2 (aa 833-1187) in yeast, was removed from pACT2 by *SfiI/NhoI* digest, and was subcloned into pCMV-HA (BD Clontech). The full-length human Rack-1 cDNA was generated by RT-PCR from human peripheral blood lymphocytes, and was subcloned into pCR2.1-TOPO (Invitrogen Life Technologies, Carlsbad, CA). *HindIII-ApaI*, *AhoI*, *BamHI-EcoRI*, *BglII-EcoRI*, and *BamHI* fragments of the full-length Rack-1 were subcloned into the Flag-tagged mammalian expression plasmid pCMV-Tag2 (BD Clontech) to generate Rack-1 (aa 1-317), (aa125-317), (aa 204-317), (aa 258-317), and (aa 1-204) indicated in Fig. 3C. Rack-1 (1-137) was generated by PCR using Rack-1 in pCR2.1-TOPO as the template, and was subcloned into the *BamHI* site in pCMV-Tag2. Rack-1 (Δ 138-203) was generated by ligation of the aa 1-137 fragment to the 204-317 fragment in pCMV-Tag2.

Oligonucleotide-directed mutagenesis was used to substitute phenylalanine for tyrosine at residues 140, 194, 228, and 246 of wild-type Rack-1 in pCMV-Tag2. The Transformer site-directed mutagenesis kit was used according to the manufacturer's protocol (BD Clontech) with the following oligonucleotides: Y140F oligo. GGTGTGTGCAAAATTCAGTCCAG; Y194F oligo. CACACAGGCTTCTGAAACACGGTG; Y228F oligo. GGCAAACACCTTTTCACGCTAGAT; Y246F oligo. CCTAACCGCTTCTGGCTGTGTGCT.

Cell culture and transfection

HEK293T cells were plated at $2-4 \times 10^6$ cells/ml in DMEM (Sigma-Aldrich) containing 10% heat-inactivated FBS (JRH Biosciences, Lenexa, KS), 2 mM L-glutamine (Invitrogen Life Technologies, Gaithersburg, MD), MEM nonessential amino acids (Invitrogen Life Technologies), 1 mM sodium pyruvate (Invitrogen Life Technologies), 100 U/ml penicillin, and 10 μ g/ml streptomycin (Invitrogen Life Technologies), and grown at 37°C in 5% CO₂ to 60% confluence. 293T cells were transfected with 10 μ g of plasmid DNA using the calcium phosphate precipitation protocol. Cells were cultured to almost 100% confluence and harvested, after appropriate stimulation.

The IL-3-dependent cell line, BAF/3, was maintained in RPMI 1640 medium supplemented with 10% FCS and IL-3.

Immunoprecipitation and immunoblotting

Cells were lysed as previously described (16). Cell lysates were centrifuged at $12,000 \times g$ for 15 min to remove debris. For immunoprecipitation, the indicated Abs were added to the supernatant of each sample, incubated for 8 h, and mixed with protein A-agarose (Sigma-Aldrich). Total cell lysates or immunoprecipitated proteins were resolved by SDS-PAGE and transferred to nitrocellulose membranes (Amersham Biosciences, Uppsala, Sweden). Membranes were probed using the appropriate Abs and visualized by ECL (Amersham Biosciences).

Immunofluorescence

HEK293T cells were maintained in DMEM containing 10% FCS and transfected with Flag-tagged wild-type or E mutant Rack-1 with or without Tyk2, Jak1, Jak2, the Jak1 KE mutant, or the Jak2 KE mutant by the calcium phosphate precipitation protocol. Forty-eight hours after transfection, cells were fixed with a solution containing 4% paraformaldehyde and incubated with an anti-Flag Ab. The cells were then incubated with a FITC-conjugated anti-mouse IgG Ab (Jackson ImmunoResearch Laboratories, West Grove, PA) and mounted with a drop of Vectashield mounting medium (Vector Laboratories, Burlingame, CA). Cells were observed using a confocal laser fluorescence microscope. The intracellular localization of labeled Rack-1 was assessed in reference to nuclear 4',6'-diamidino-2-phenylindole dihydrochloride (DAPI) staining. The digital images were processed by layering and the contrast of all images was increased by 50% using Adobe Photoshop 4.0 (Adobe Systems, Mountain View, CA). Nuclear DAPI staining appears blue and Rack-1 appears green.




FIGURE 1. Rack-1 interacts with Tyk2. *A*, A schematic representation of the Rack-1 protein identified by yeast two-hybrid screen using the Tyk2 tyrosine kinase domain as bait. Amino acids 137-317 of Rack-1 were present in three clones which interacted with Tyk2 in yeast cells. *B*, Coimmunoprecipitation of clone 4-86 with Tyk2 in mammalian 293T cells. 293T cells were transfected with clone 4-86 and/or Tyk2. Cell lysates were immunoprecipitated with anti-Tyk2 Ab, and immunoblotted with anti-Rack-1 Ab.




FIGURE 2. The physical interaction between Rack-1 and Tyk2 is independent of IFN stimulation. *A*, 293T cells were transfected with Tyk2 and/or Rack-1. *Top*, Cell lysates were immunoprecipitated with anti-Rack-1 Ab and immunoblotted with anti-Tyk2 (*upper panel*) or anti-Rack-1 Ab (*lower panel*). Open arrow indicates transfected Rack-1, and the filled arrow indicates endogenous Rack-1. *Bottom*, Cell lysates were immunoprecipitated with anti-Tyk2 Ab and immunoblotted with anti-Rack-1 Ab (*upper panel*) or anti-Tyk2 Ab (*lower panel*). *B*, BAF/3 cells were either stimulated for the indicated time with IFN- α (1000 U/ml) or left unstimulated as a control. Cell lysates were immunoprecipitated with non-specific mouse IgG or anti-Rack-1 Ab and immunoblotted with anti-Tyk2 Ab (*upper panel*) or anti-Rack-1 Ab (*lower panel*).

Results

Identification of Rack-1 as a Tyk2-interacting protein

To identify novel Tyk2-interacting proteins, a yeast two-hybrid screen was performed using the kinase domain of Tyk2 fused to the Gal DNA-binding domain as bait. A human bone marrow cell cDNA library was screened. Among a number of positive clones, three clones termed 4-6, 4-86, and 4-160, encoded the C-terminal portion of the previously described Rack-1 (Fig. 1A). To determine whether these clones encoded a protein able to interact with Tyk2 in mammalian cells, clone 4-86 was subcloned into the mammalian expression vector pCMV-HA. The resulting expression vector produced a protein that interacted strongly with Tyk2 in 293T cells (Fig. 1B), suggesting that the region comprising aa 137-317 of Rack-1 contains the binding site for Tyk2.

We next examined the association between Tyk2 and Rack-1 using the full-length cDNA in mammalian cells. The full-length Flag tagged Rack-1 cDNA was transiently transfected into 293T cells with or without the full-length Tyk2 expression vector. Fig. 2A shows that Tyk2 coimmunoprecipitated with Rack-1 and Rack-1 coimmunoprecipitated with Tyk2 when both Tyk2 and Rack-1 were expressed in

293T cells. We next investigated whether endogenous Rack-1 was able to interact with Tyk2 and how this might be affected by the activation of Tyk2. To activate Tyk2, a mouse pro-B cell line, BAF/3, was stimulated or not stimulated with IFN- α . Tyk2 immunoprecipitates were assessed for the presence of endogenous Rack-1 by Western blotting. As can be seen in Fig. 2B, Tyk2 was present in the Rack-1 immunoprecipitates. Furthermore, equivalent amounts of Tyk2 were present in samples which had or had not been stimulated with IFN- α . This indicates that Rack-1 associates with Tyk2 in BAF/3 cells, and that this interaction is not altered by stimulation with IFN- α .

Mapping the sites in Tyk2 and Rack-1 required for binding

We next sought to determine which region of Tyk2 was responsible for the interaction with Rack-1. We separated the Tyk2 cDNA into four regions (Fig. 3A), and each region was subcloned in frame with a *myc* tag in the mammalian expression vector pCMV-Myc. The full-length Tyk2 construct or each partial Tyk2 construct was transiently transfected into 293T cells along with the full-length Rack-1 construct. Cell lysates were immunoprecipitated with anti-Tyk2 or anti-Myc Ab, and Western blotted with




FIGURE 3. Mapping the sites in Tyk2 and Rack-1 required for binding. *A*, A schematic of the domain structure of Tyk2 and the mutant fragments. *B*, Full-length Tyk2 or Myc-tagged Tyk2 mutants were coexpressed with Flag-tagged Rack-1 in 293T cells. Forty-eight hours after transfection, the cells were lysed and immunoprecipitations were performed with anti-Tyk2 or anti-Myc Ab. The immunoprecipitates were immunoblotted with anti-Flag Ab (upper panel), anti-Tyk2 Ab (middle panel), or anti-Myc Ab (lower panel). *C*, A schematic of the domain structure of Rack-1 and the mutant fragments. *D*, Rack-1 mutants were coexpressed with Tyk2 in 293T cells. Forty-eight hours after transfection, the cells were lysed and immunoprecipitations were performed with anti-Tyk2 Ab. The immunoprecipitates were immunoblotted with anti-Flag Ab (upper panel) or anti-Tyk2 Ab (lower panel).

anti-flag Ab. Fig. 3B shows that Rack-1 interacted with Tyk2 (266–733) and Tyk2 (600–1086) as well as full-length Tyk2. In addition, Rack-1 interacted weakly with Tyk2 (833–1187), which contains the kinase domain of Tyk2. As Rack-1 did not interact with Tyk2 (1–450), these data indicate that Rack-1 interacts weakly with the kinase domain of Tyk2 and interacts strongly with the pseudokinase domain of Tyk2. Furthermore, as there is no overlapping region in Tyk2 (266–733) and Tyk2 (833–1187), there is the possibility that multiple RACK-1 binding sites exist in Tyk2.

We next determined the region of Rack-1 required for the interaction with Tyk2. Fig. 3C shows the full-length and deletion mutants of Rack-1 used in this experiment. As shown in Fig. 3D, full-length Rack-1 (1–317), Rack-1 (125–317), and Rack-1 (1–204) bound to Tyk2. The C-terminal region of Rack-1 (aa 204–317) did not associate with Tyk2. Taken together with the fact that the two-hybrid candidate clone 4-86 encodes aa 137–317 of Rack-1, these data suggest that the middle portion of Rack-1, aa 137–203, may associate with Tyk2. We next examined the binding of Rack-1 Δ 138–203, which lacks aa 138–203, to Tyk2. Unexpectedly, Rack-1 Δ 138–203 also binds to Tyk2 (Fig. 3D). This indicates that two regions of Rack-1, the N terminus and the middle portion, might bind to Tyk2. This was confirmed by the fact that Rack-1 (1–137) binds to Tyk2 (Fig. 3D).

Rack-1 is phosphorylated on Tyr¹⁹⁴, a residue in the fifth WD repeat, by Jaks

As Tyk2 is a tyrosine kinase, we assessed whether Rack-1 could be phosphorylated by Tyk2. When Rack-1 was transiently cotransfected into 293T cells with Tyk2, Rack-1 was phosphorylated by Tyk2 (Fig. 4A). There are six tyrosine residues in Rack-1; to identify the specific tyrosine residue(s) that is phosphorylated by Tyk2 in vivo, we performed site-directed mutagenesis, substituting phe-

nylalanine for tyrosine at individual and multiple sites in Rack-1 (Fig. 4B). The Rack-1 mutants were then transiently coexpressed with Tyk2 in 293T cells, and proteins were immunoprecipitated with anti-Rack-1 and subjected to immunoblot analysis with anti-phosphotyrosine (Fig. 4C). We found that the Rack-1 mutants containing phenylalanine at position 194 (the E, F, H, and I mutants) were not phosphorylated by Tyk2. Because the Rack-1 E mutant is a single substitution of tyrosine 194 to phenylalanine and this mutant is not phosphorylated, Tyk2 must phosphorylate Rack-1 on Tyr¹⁹⁴. In addition, the immunoprecipitates of all Rack-1 mutants contained phosphorylated Tyk2, indicating that the tyrosine phosphorylation of Rack-1 has no influence on the association of Rack-1 and Tyk2. This result was confirmed by the transient transfection of wild type or the E mutant of Rack-1 with or without Tyk2 in 293T cells. Proteins were immunoprecipitated with Tyk2 or Rack-1. The results shown in Fig. 5 demonstrate that Rack-1 was present in the Tyk2 immunoprecipitates at equivalent levels whether aa 194 of Rack-1 was tyrosine or phenylalanine. In addition, Tyk2 was present in the Rack-1 immunoprecipitates at equivalent amounts. Taken together, these results demonstrate that phosphorylation of tyrosine 194 of Rack-1 is not important for the interaction of Rack-1 and Tyk2.

We next examined whether other Jaks could phosphorylate Rack-1. In addition to Tyk2, Jak1, Jak2, and Jak3 were able to phosphorylate Rack-1 (Fig. 6). We also transfected kinase-dead Jak1 or Jak2 (KE mutant) with Rack-1 into 293T cells (Fig. 6, lane 3 and 5). In this case, Rack-1 was not phosphorylated, although Rack-1 associated with Jak1KE and Jak2KE. This indicates that Jaks directly phosphorylate Rack-1. Furthermore, none of the Jak family kinases phosphorylated the Rack-1 E mutant (Fig. 6, right), indicating that all Jaks phosphorylate Rack-1 on a single tyrosine, residue 194. Notably, immunoprecipitates containing the Rack-1 E




FIGURE 4. Tyk2 phosphorylates Rack-1 on Tyr¹⁹⁴, a residue in the fifth WD repeat. *A*, Rack-1 is phosphorylated by Tyk2. Tyk2 and/or Flag-tagged Rack-1 were expressed in 293T cells. Total cell lysates were immunoprecipitated with anti-Flag Ab and immunoblotted with anti-phosphotyrosine Ab (upper panel) or anti-Flag Ab (lower panel). *B*, Site-directed mutagenesis of Rack-1 was performed to substitute phenylalanine for tyrosine at individual and multiple sites. *C*, Tyk2 phosphorylates Rack-1 on Tyr¹⁹⁴, a residue in the fifth WD repeat. 293T cells were transfected with a series of wild-type or Rack-1 mutants. Forty-eight hours after transfection, cells were lysed, immunoprecipitated with anti-Rack-1 Ab, and immunoblotted with anti-phosphotyrosine Ab (upper panel) or anti-Rack-1 Ab (lower panel). The arrows indicate tyrosine phosphorylated Rack-1 and Tyk2 which coimmunoprecipitates with Rack-1.



FIGURE 5. Tyrosine phosphorylation of Rack-1 has no influence on the association between Rack-1 and Tyk2. Empty vector (pCMV-Tag2A), wild-type Rack-1, or the Rack-1 E mutant (Y194F) were coexpressed with Tyk2 in 293T cells. Total cell lysates were immunoprecipitated with anti-Tyk2 Ab (*left panel*) or anti-Rack-1 Ab (*right panel*) and immunoblotted with anti-Tyk2 Ab (*upper panel*) or anti-Rack-1 Ab (*lower panel*).

mutant contained Jak1, Jak2, Jak3, and Tyk2. Therefore, Jaks associate with Rack-1 whether Rack-1 is tyrosine phosphorylated or not.

Perinuclear translocation of Rack-1 by Jaks

293T cells were used to localize the distribution of Rack-1 within cells with or without the activation of Jaks (Fig. 7A). When Rack-1 was transfected into 293T cells, it was detected throughout the cytoplasm. When both Rack-1 and Tyk2 were transfected into 293T cells, intracellular redistribution of Rack-1 toward the perinuclear area was observed. The transfection of Jak1 or Jak2 with Rack-1 in 293T cells also induced the perinuclear translocation of Rack-1. To determine whether the perinuclear translocation of Rack-1 was induced by Jaks, we transfected the Jak1 KE mutant or the Jak2 KE mutant with Rack-1 in 293T cells. Under these conditions, Rack-1 was detected throughout the cytoplasm, and was not translocated to the perinuclear region. Next, we examined whether perinuclear translocation of Rack-1 required the phosphorylation of Rack-1. When the Rack-1 E mutant (Y194F) was transfected with Tyk2 into 293T cells, perinuclear translocation of the Rack-1 E mutant was observed to the same extent as Rack-1 wild type (Fig. 7B).

Discussion

The main substrates of Jaks are the Stats, and the phosphorylation of Stats is essential for the biological activities of cytokines (2). Analysis of Stat-deficient mice has demonstrated that Stats transduce almost all cytokine signaling (17). In the case of inhibition of IL-7-induced B cell growth by IFN- α , Stat1 activation was not required (12), although we found that Tyk2 activation was necessary (11). To find Tyk2-activated signaling molecules other than the Stats, we performed a yeast two-hybrid screen for proteins that associated with Tyk2. We found that Rack-1, which was originally described as a receptor for activated protein kinase C (PKC)- β (18), associated with Tyk2 (Fig. 1). Interestingly, it has recently been reported that Rack-1 associates with the β -chain of the type I IFNR and recruits Stat1 to the receptor complex. This raises the possibility that Rack-1 serves as a scaffolding protein during cytokine signal transduction. We have shown here that Tyk2 associates with Rack-1 in 293 T cells and BAF/3 cells (Fig. 2). This association was not altered by stimulation with IFN- α (Fig. 2B). Recently, Usacheva et al. (14) reported that Tyk2 and Jak1 associated with Rack-1 using GST-fusion proteins. Consistent with our result, they also reported that association of Jak1 and Rack-1 was not affected by IFN- β treatment. Additionally, we have determined the binding sites on Tyk2 and Rack-1. Tyk2 binds strongly to Rack-1 through the kinase domain, and binds weakly through the pseudo-




FIGURE 6. In addition to Tyk2, Jak1, Jak2, and Jak3 phosphorylate tyrosine 194 on Rack-1. Wild-type or the Rack-1 E mutant (Y194F) were coexpressed with either Jak1, the Jak1 KE mutant, Jak2, the Jak2 KE mutant, Jak3, or Tyk2 in 293T cells. Total cell lysates were immunoprecipitated with anti-Rack-1 Ab and immunoblotted with anti-phosphotyrosine Ab, anti-Rack-1 Ab, or anti-Jak Abs (mixture or individual anti-Jak1, anti-Jak2, and anti-Tyk2 Abs) as indicated.


kinase domain (Fig. 3B). Therefore, Tyk2 probably associates with Rack-1 through more than one binding site. Similarly, Rack-1 binds to Tyk2 through two regions, one in the N terminus and one in the middle portion of the protein (aa 137–203) (Fig. 3D).

As Tyk2 is a tyrosine kinase, we next analyzed whether Rack-1 could serve as a substrate of Tyk2. When Tyk2 and Rack-1 were transiently transfected into 293T cells, Rack-1 was phosphorylated by Tyk2 (Fig. 4A). In addition to Tyk2, other members of the Jak family (Jak1, Jak2, and Jak3) phosphorylated Rack-1 (Fig. 6). Kinase-dead Jaks (Jak1 KE or Jak2 KE mutants) were unable to phosphorylate Rack-1, suggesting that Jaks directly phosphorylate Rack-1.

When cells are stimulated by PMA, PKC is activated and Src phosphorylates Rack-1 on Tyr²²⁸ and/or Tyr²⁴⁶ (19). Therefore, we wanted to determine whether the site of Tyk2 phosphorylation was the same as the site of Src phosphorylation. We demonstrated that the A (Y-228-F), B (Y-246-F), and C (Y-228, 246-F) mutants of Rack-1 were phosphorylated by Tyk2 (Fig. 4C). Next, we substituted tyrosine 140 and/or 194 to phenylalanine. The substitution of tyrosine 194 to phenylalanine in Rack-1 (this mutation is present in the E, F, H, and I mutants) diminished the phosphorylation of Rack-1 by Tyk2 (Fig. 4C). In addition to Tyk2, other members of the Jak family (Jak1, Jak2, and Jak3) phosphorylated tyrosine 194 on Rack-1 (Fig. 6). Therefore, Jaks phosphorylate only tyrosine 194 of Rack-1. In addition, these results indicate that Jaks and Src kinase phosphorylate different tyrosine residues on Rack-1.

Although the binding of Rack-1 to Src required the phosphorylation of Rack-1 (19), Rack-1 mutants (E, F, H, and I) which were not phosphorylated by Tyk2 were still able to associate with Tyk2 (Fig. 4C). Indeed, wild-type Rack-1 and the Rack-1 E mutant associated with Tyk2 to the same degree (Fig. 5). These results indicate that the association of Rack-1 and Tyk2 occurred regardless of Rack-1 phosphorylation, and this association is not enhanced by tyrosine phosphorylation of Rack-1. In addition, catalytic activity

FIGURE 7. Localization of Rack-1. *A*, Flag-tagged Rack-1 (wild type or E mutant) was expressed either alone or in combination with one of Tyk2, Jak1, the Jak1 KE mutant, Jak2, or the Jak2 KE mutant in 293T cells. After 48 h, the localization of tagged proteins was visualized by confocal microscopy. *B*, The number of cells showing perinuclear localization of Rack-1 was calculated. Data represent the mean with SD of four different experiments.



of Jaks is not essential for binding to Rack-1, as the KE mutants of both Jak1 and Jak2 associated with Rack-1 (Fig. 6). This result is consistent with previous observations that Rack-1 associated with Tyk2 in BAF/3 cells in the presence or absence of IFN- α stimulation (Fig. 2B).

IFN- β stimulation has been reported to translocate Rack-1 toward the perinuclear region (13). Transient expression of Jaks in 293T cells led to the autophosphorylation of the Jaks. When Rack-1 alone was transfected into 293T cells, Rack-1 was present throughout the cytoplasm. In contrast, when both Jak (Jak1, Jak2 or Tyk2) and Rack-1 were transfected into 293T cells, Rack-1 was translocated to the perinuclear region (Fig. 7). This perinuclear translocation was not observed when Jak1 KE or Jak2 KE was cotransfected with Rack-1, indicating that the kinase activity of Jaks is required for the translocation of Rack-1. As Tyk2 phosphorylated Rack-1, and as the kinase activity was essential for the perinuclear translocation of Rack-1, it was possible that phosphorylated Rack-1 might translocate to the perinuclear region. To test this hypothesis, we transfected Tyk2 and the Rack-1 E mutant, which lacks tyrosine 194, the residue that is phosphorylated by Jaks. Surprisingly, the Rack-1 E mutant translocated to the perinuclear region in a similar manner as wild-type Rack-1 (Fig. 7). One possible explanation for this observation is that Tyk2 might phosphorylate another target, which forms a complex with Rack-1, and translocates Rack-1 to the perinuclear region. Another possible explanation is that Tyk2 might phosphorylate endogenous Rack-1 in 293T cells, this phosphorylated endogenous Rack-1 might form a complex with the transfected Rack-1 E mutant, and the two types of Rack-1 might then be translocated to the perinuclear region together. To determine the precise mechanism of Rack-1 translocation, similar analysis must be performed using Rack-1 null cells.

In summary, we have demonstrated that Rack-1 associates with Jaks. Specifically, Rack-1 interacts with the pseudokinase and kinase domains of Tyk2. Two regions of Rack-1, the N terminus and

the middle portion of the protein (aa 138–203), contribute to binding Tyk2. In addition, we have shown that tyrosine 194 of Rack-1 is phosphorylated by Jaks. Neither the phosphorylation state of Rack-1 nor of the Jak has an influence on the association of the two proteins. Furthermore, Rack-1 is translocated to the perinuclear region by the activation of Jaks.

The function of Rack-1 in cytokine signaling is still unclear. Because Rack-1 is a WD repeat-containing protein with no enzymatic activity (20), and because Rack-1 binds to PKC, Src homology 2-containing proteins such as Src, phospholipase C γ , and *ras*-GTPase-activating proteins (21, 22), it has been reported that Rack-1 functions as a scaffold protein that recruits specific signaling elements. Rack-1 also binds to the IFNR β -chain (13), Stat1 (15), and, as we have shown here, Jaks. It is possible that Rack-1 functions as a scaffold protein that aligns the signaling molecules in the cytokine-signaling cascade. Additionally, the fact that Rack-1 is phosphorylated by Jaks and is translocated to the perinuclear region by activation of Jaks raises the possibility that Rack-1 functions as a signaling molecule in the cytokine signaling cascade.

Acknowledgments

We thank M. Sato and M. Ito for their excellent technical assistance.

References

1. Ihle, J. N. 1995. Cytokine receptor signalling. *Nature* 377:591.
2. Ihle, J. N., T. Nosaka, W. Thierfelder, F. W. Quelle, and K. Shimoda. 1997. Jaks and Stats in cytokine signaling. *Stem Cells* 15(Suppl. 15):105.
3. Velazquez, L., M. Fellous, G. R. Stark, and S. Pellegrini. 1992. A protein tyrosine kinase in the interferon α/β signaling pathway. *Cell* 70:313.
4. Darnell, J. E., Jr., I. M. Kerr, and G. R. Stark. 1994. Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. *Science* 264:1415.
5. Shimoda, K., K. Kato, K. Aoki, T. Matsuda, A. Miyamoto, M. Shibamori, M. Yamashita, A. Numata, K. Takase, S. Kobayashi, et al. 2000. Tyk2 plays a restricted role in IFN α signaling, although it is required for IL-12-mediated T cell function. *Immunity* 13:561.

6. Karaghiosoff, M., H. Neubauer, C. Lassnig, P. Kovarik, H. Schindler, H. Pircher, B. McCoy, C. Bogdan, T. Decker, G. Brem, et al. 2000. Partial impairment of cytokine responses in Tyk2-deficient mice. *Immunity* 13:549.
7. Rodig, S. J., M. A. Meraz, J. M. White, P. A. Lampe, J. K. Riley, C. D. Arthur, K. L. King, K. C. Sheehan, L. Yin, D. Pennica, et al. 1998. Disruption of the Jak1 gene demonstrates obligatory and nonredundant roles of the Jaks in cytokine-induced biologic responses. *Cell* 93:373.
8. Meraz, M. A., J. M. White, K. C. Sheehan, E. A. Bach, S. J. Rodig, A. S. Dighe, D. H. Kaplan, J. K. Riley, A. C. Greenlund, D. Campbell, et al. 1996. Targeted disruption of the Stat1 gene in mice reveals unexpected physiologic specificity in the JAK-STAT signaling pathway. *Cell* 84:431.
9. Durbin, J. E., R. Hackenmiller, M. C. Simon, and D. E. Levy. 1996. Targeted disruption of the mouse Stat1 gene results in compromised innate immunity to viral disease. *Cell* 84:443.
10. Park, C., S. Li, E. Cha, and C. Schindler. 2000. Immune response in Stat2 knock-out mice. *Immunity* 13:795.
11. Shimoda, K., K. Kamesaki, A. Numata, K. Aoki, T. Matsuda, K. Oritani, S. Tamiya, K. Kaio, K. Takase, R. Imamura, et al. 2002. Cutting edge: Tyk2 is required for the induction and nuclear translocation of Daxx which regulates IFN- α -induced suppression of B lymphocyte formation. *J. Immunol.* 169:4707.
12. Gongora, R., R. P. Stephan, R. D. Schreiber, and M. D. Cooper. 2000. Stat-1 is not essential for inhibition of B lymphopoiesis by type I IFNs. *J. Immunol.* 165:2362.
13. Croze, E., A. Usacheva, D. Asanow, R. D. Minshall, H. D. Perez, and O. Colamonici. 2000. Receptor for activated C-kinase (RACK-1), a WD motif-containing protein, specifically associates with the human type I IFN receptor. *J. Immunol.* 165:5127.
14. Usacheva, A., X. Tian, R. Sandoval, D. Salvi, D. Levy, and O. R. Colamonici. 2003. The WD motif-containing protein RACK-1 functions as a scaffold protein within the type I IFN receptor-signaling complex. *J. Immunol.* 171:2989.
15. Usacheva, A., R. Smith, R. Minshall, G. Baida, S. Seng, E. Croze, and O. Colamonici. 2001. The WD motif-containing protein receptor for activated protein kinase C (RACK1) is required for recruitment and activation of signal transducer and activator of transcription 1 through the type I interferon receptor. *J. Biol. Chem.* 276:22948.
16. Shimoda, K., J. Feng, H. Murakami, S. Nagata, D. Watling, N. C. Rogers, G. R. Stark, I. M. Kerr, and J. N. Ihle. 1997. Jak1 plays an essential role for receptor phosphorylation and Stat activation in response to granulocyte colony-stimulating factor. *Blood* 90:597.
17. Ihle, J. N. 1996. STATs: signal transducers and activators of transcription. *Cell* 84:331.
18. Ron, D., C. H. Chen, J. Caldwell, L. Jamieson, E. Orr, and D. Mochly-Rosen. 1994. Cloning of an intracellular receptor for protein kinase C: a homolog of the β subunit of G proteins. *Proc. Natl. Acad. Sci. USA* 91:839.
19. Chang, B. Y., R. A. Harte, and C. A. Cartwright. 2002. RACK1: a novel substrate for the Src protein-tyrosine kinase. *Oncogene* 21:7619.
20. Neer, E. J., C. J. Schmidt, R. Nambudripad, and T. F. Smith. 1994. The ancient regulatory-protein family of WD-repeat proteins. *Nature* 371:297.
21. Chang, B. Y., K. B. Conroy, E. M. Machleder, and C. A. Cartwright. 1998. RACK1, a receptor for activated C kinase and a homolog of the β subunit of G proteins, inhibits activity of src tyrosine kinases and growth of NIH 3T3 cells. *Mol. Cell Biol.* 18:3245.
22. Chang, B. Y., M. Chiang, and C. A. Cartwright. 2001. The interaction of Src and RACK1 is enhanced by activation of protein kinase C and tyrosine phosphorylation of RACK1. *J. Biol. Chem.* 276:20346.

The FASEB Journal express article 10.1096/fj.04-2396fje. Published online October 5, 2004.

Human cord blood- and bone marrow-derived CD34⁺ cells regenerate gastrointestinal epithelial cells

Fumihiko Ishikawa,* Masaki Yasukawa,[†] Shuro Yoshida,* Kei-ichiro Nakamura,[‡] Yoshihisa Nagatoshi,[§] Takaaki Kanemaru,^{||} Kazuya Shimoda,* Shinji Shimoda,* Toshihiro Miyamoto,* Jun Okamura,[§] Leonard D. Shultz,[¶] and Mine Harada*

*Department of Medicine and Biosystemic Science, Kyushu University Graduate School of Medicine, Fukuoka, Japan; [†]First Department of Internal Medicine, Ehime University School of Medicine, Shigenobu, Japan; [‡]Second Department of Anatomy, Kurume University, Kurume, Japan; [§]Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan; ^{||}Morphology Core, Kyushu University, Fukuoka, Japan; [¶]The Jackson Laboratory, Bar Harbor, ME

Corresponding author: Fumihiko Ishikawa, Kyushu University Graduate School of Medicine, Department of Medicine and Biosystemic Science, 3-1-1 Maidashi, Higashi-ku, Fukuoka 812-8582, Japan. E-mail: f_ishika@intmed1.med.kyushu-u.ac.jp

ABSTRACT

In the present study, we aimed to clarify the capacity of human cord blood- and bone marrow-derived progenitor cells to generate gastrointestinal epithelial cells in clinical and experimental transplantation settings. First, in a clinical transplantation setting, gastrointestinal tissues derived from female pediatric or juvenile recipients of allogeneic sex-mismatched bone marrow and cord blood transplantation were examined for the presence of donor-derived epithelial cells. Gastrointestinal specimens of allogeneic recipients included Y chromosome⁺ cytokeratin⁺ epithelial cells at a frequency of 0.4–1.9%. To further determine the capacity of purified human progenitor cells, human cord blood- or bone marrow-derived CD34⁺ cells were transplanted into newborn NOD/SCID/ β 2-microglobulin^{null} mice as an experimental transplantation assay. When gastrointestinal tissues derived from recipient mice were subjected to FISH and immunofluorescence analyses, human epithelial cells were identified at a frequency of 0.24–0.58% at 3 months posttransplantation. Finally, double FISH analyses using species-specific probes revealed that human chromosome⁺ epithelial cells did not possess any murine chromosomes, indicating that donor-derived epithelial cells were not generated only by cell fusion. On the basis of these findings, it is concluded that purified human cord blood and bone marrow CD34⁺ progenitor cells can generate gastrointestinal epithelial cells across allogeneic and xenogeneic histocompatibility barriers.

Key words: stem cell • plasticity • fusion • epithelium

At the very end of the 20th century, Petersen et al. (1) reported that bone marrow (BM) cells possessed an extensive capacity to generate hepatocytes as well as hematopoietic cells. The notion that BM-derived progenitor cells are capable of generating